Mission: Dedicated to finding a cure for Angelman Syndrome and related disorders through the funding of an aggressive research agenda, education, and advocacy.
Results: Minocycline Clinical Trials commenced April 2012
Target demographics: by raising funds to research therapeutics
Geographic areas served: supporting those affected by Angelman Syndrome
Programs: Fast's primary goal is to advance research leading to a cure for as.
as as is a rare disorder, the community of parents and caregivers of individuals with as rely heavily on social networking to become informed and seek advice and guidance on the challenges which the disorder presents. Its is one of fast's objectives to educate, support, and strengthen this community. In december 2014, fast brought together 527 parents/caregivers to hear about the latest research on as, the goals and objectives of fast, its progress towards meeting those goals and plans for the future. Speakers included the head of fast's scientific advisory board, dr. Edwin weeber, who cured as in the mouse model, as well as dr. Rebecca burdine, fast's chief science officer, colin farrell, jai courtney, retta sirleaf and paula evans. In addition, networking/mentoring opportunities were facilitated so that people caring for individuals of the same age or with similar circumstances could exchange experiences, information and guidance and solidify relationships.
literacy and advancing adventures in communicating camp for individuals with angelman syndrome and their families.